EQL Share Price Performance
SEK 0
-85.40 (-100.00%)
Price SEK 0
Fair ValueSEK 86.37
Share Pricen/a
EQL Pharma AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
EQL Community Narratives
MA
Fair Value SEK 86.37 28.8% undervalued intrinsic discount
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value SEK 80 23.1% undervalued intrinsic discount
European Market Expansion And Pipeline Development Will Unlock Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.Read more
138
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
MA
SEK 86.37
28.8% undervalued intrinsic discount
Mandelman's Fair Value
Revenue
21.49% p.a.
Profit Margin
15%
Future PE
25x
Price in 2029
SEK 115.56
European Market Expansion And Pipeline Development Will Unlock Potential
Key Takeaways Enlarged European market reach and a deep pipeline of generics underpin prospects for robust, sustained revenue and margin growth. Operational efficiencies, disciplined acquisitions, and targeted R&D boost earnings quality and position EQL Pharma for enhanced resilience and market value.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 80
23.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
30.6% p.a.
Profit Margin
17.19%
Future PE
17.15x
Price in 2029
SEK 90.28
Trending Discussion
Recently Updated Narratives
MA
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
Fair Value: SEK 86.37 28.8% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Fair Value: SEK 80 23.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
EQL Pharma AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 08, 2026
- 0.99
- 41.19%
- 6.89%
- 162.0%
About EQL
- Founded
- 2006
- Employees
- 55
- CEO
- WebsiteView website
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
